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Herbal or botanical remedies consumption by the public is on 
the increase in the western world [1,2]. This demand is often rooted 
in the belief that herbal products, being natural, are safe to take and 
can contribute positively to the management of disease states. This 
tendency of using natural products for managing illnesses is by no 
means new to health care [2]. While the earlier demand for herbs has 
been diminished due to the new advances in drug synthesis, a review 
of current drugs revealed a high percentage of them (about 25%) still 
had a botanical origin [3]. In response to the public’s demand for a 
better recognition of the natural products in health care, the United 
States Congress established in 1994 the Dietary Supplements Health 
and Education Act, also known as DSHEA. According to DSHEA, 
dietary supplements (DS) are “intended to supplement the diet” by 
providing the consumer with specific nutrients including vitamins, 
minerals, herbs, amino acids, and others [2,4]. As such, the intention 
of DSHEA was not to use these products for the management of disease 
state, but rather to use them as “supplements” to the regular diet. The 
US Food and Drug Administration (FDA) is the Federal agency that 
regulates DS products available on the US market, while the Federal 
Trade Commission monitors the “truth-in-advertising” claims 
for any misleading information in DS advertisements [4]. Unlike 
prescription or over-the-counter medications, DS manufacturers 
do not have to submit to the FDA any safety or efficacy data prior to 
marketing. In fact, it is the FDA’s responsibility to monitor the safety 
of DS while they are being consumed by the public [2,4]. The current 
Federal regulations require the manufacturer of DS to formulate and 
package them under cGMP-controlled (current Good Manufacturing 
Practice) environment [4]. The label on DS products usually contain 
information related to the “structure-function” relationship that 
a product is intended to provide, however it cannot state that the 
product is useful for treating a specific “medical” condition. For 
example, it can be stated on the label that St. John’s Wort (Hypericum 
perforatum) is useful as a “mood enhancer,” but the manufacturer 
cannot claim the herb’s usefulness in treating clinical depression. 
Additional information on the standardized product’s label lists the 
component(s) to which the standardization was based upon. For 
Hypericum perforatum products, these are standardized with respect 
to hypericin which is one of the “active” constituents in St. John’s Wort.
Some of the major concerns in health care are drug interactions. 
The use of DS along with medications can result in drug-herb 
interactions. Clinical investigations have documented major drug-
herb interactions especially those seen with sedative, anti-diabetic, 
and anti-coagulation medications [2]. Moreover, there is a lack of 
communication existing between the patients and their clinicians 
concerning DS use; only 1 out of 4 patients communicates with 
their physicians about DS use [5]. In addition, most consumers get 
the information about DS products from friends and relatives and 
not from their health care providers [6]. This combination of factors 
presents a real concern in our current health care system. Some of 
the DS products can produce serious side/toxic effects on their own 
[4], and some are found adulterated with pharmaceutical drugs, 
a problem often encountered with imported Traditional Chinese 
Medicine products [5,7].
Research in the area of botanical medicine has been inadequate 
in its quality and quantity. This is perhaps related to the limited 
availability of funding from the government. The US government 
makes some fund available to researchers through its agencies 
such as the National Center for Complementary and Alternative 
Medicine (NCCAM) (National Institutes of Health). In addition, 
there is a broad “dis-interest” by the pharmaceutical industry to 
devote more time and money for scientific investigations related to 
DS products. Review articles in the area of botanical medicine often 
cite the various shortfalls of research which include inadequate 
sample size, unacceptable experimental design, and/or various host 
of methodological issues [8]. To overcome this negativity which is 
often associated with DS research, more utilization of randomized 
placebo-controlled clinical trial (RCTs) along with the use of 
acceptable state of art scientific methodologies would certainly usher 
a new era of discoveries. With respect to RCTs, researchers must 
provide detailed information describing the patient population (age, 
gender, weight, disease state, etc.) along with a clear description of 
the randomization method, which is chosen in the research. In 
addition, researchers must report all adverse events and side effects 
documented during the course of the study. One of the major flaws in 
this area is the lack of information pertaining to the DS product being 
investigated, as preparations of the same botanical can vary greatly in 
their composition [2]. Researchers in this area must use well-defined 
standardized DS products and provide characteristics that include 
the product’s natural origin (scientific name and parts of the plant 
being used), source (geographic region, manufacturer, etc.), dosage 
form (tablet, fluidextract, cream, etc.), and composition (a detailed list 
of components with their concentrations). It is known that various 
components of the same plant can produce synergistic or opposing 
pharmacologic effects on individuals when present together in the 
same formulation [e.g., ginsenosides’ effect (from Panax ginseng) on 
blood glucose level] [1]. And, knowledge of the composition assures 
that the subjects are certain to receive the desired dose of the “active” 
ingredient(s) under investigation. It is also desirable that the dietary 
supplements industry takes initiatives for identifying the toxicity 
and the teratogenicity of the various components existing in the DS 
formulation.
In conclusion, herbal preparations are being used alone or in 
combination with pharmaceutical preparations, oftentimes without 
the knowledge of the clinicians. Most consumers get their information 
on DS from friends and family members. Major research flaws are 
often encountered in the DS literature which may be remedied by 
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standardizing the herbal preparations being tested and using more 
appropriate experimental designs.
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